10-Q: Stemtech Q2 Loss Narrows Amid Sales Decline, Cost Cuts

Stemtech Corporation reported a reduced net loss in Q2 2025 despite a significant drop in net sales, driven by aggressive cost management and a strategic recalibration.

Summary

• Net sales for the three months ended June 30, 2025, were $697,925, a decrease from $1,325,800 in the same period of 2024.
• Net sales for the six months ended June 30, 2025, were $1,565,971, down from $2,708,370 in the prior year period.
• Net loss for Q2 2025 decreased to $296,280 from $784,087 in Q2 2024.
• Net loss for the six months ended June 30, 2025, decreased to $1,755,006 from $2,204,716 in the prior year period.
• Operating expenses for Q2 2025 decreased by $832,928 to $853,004, primarily due to reductions in commissions and selling/marketing expenses.
• Cost of goods sold for Q2 2025 decreased to $145,909 from $332,177 in Q2 2024, reflecting efficiency improvements.
• The company reported an accumulated deficit of approximately $32.6 million and a working capital deficiency of approximately $6.4 million as of June 30, 2025.
• Cash and cash equivalents increased slightly to $272,450 at June 30, 2025, from $255,298 at December 31, 2024.
• Net cash used in operating activities for the six months ended June 30, 2025, improved to $635,555 from $841,127 in the prior year period.
• Net cash provided by financing activities significantly increased to $552,134 for the six months ended June 30, 2025, from $68,748 in the prior year period, mainly from notes payable and factoring arrangements.

Sentiment

Score: 2

Explanation: The company faces severe financial challenges, including a significant accumulated deficit and working capital deficiency, leading to a 'going concern' warning. While management has implemented cost-cutting measures that reduced net loss, the substantial decline in sales and ongoing reliance on external financing for survival indicate a highly precarious financial position. The planned capital raises are critical but uncertain, and the overall outlook remains highly speculative.

Positives

• Net loss significantly decreased for both the three-month and six-month periods ended June 30, 2025, indicating improved cost control.
• Operating expenses were substantially reduced by $832,928 in Q2 2025 and $955,771 for the six-month period, demonstrating effective cost management initiatives.
• Cost of goods sold decreased, reflecting successful efforts to optimize manufacturing processes and manage raw material costs.
• Interest expense declined, indicating enhanced debt management strategies and efforts to optimize capital structure.
• Cash balance increased slightly to $272,450 at June 30, 2025.
• Net cash used in operating activities improved, indicating a more efficient use of cash in core operations.
• The company is actively pursuing capital raising initiatives, including a private placement of common stock expected to raise approximately $57 million by Q4 2025.
• Negotiating a convertible debt facility of up to $3 million by Q1 2026 to provide interim liquidity.
• Management expects to reduce monthly cash operating expenditures by approximately $0.5 million (20%) by the end of Q3 2025.
• Plans to increase quarterly revenue by approximately 15-20% compared to Q2 2025 levels by launching existing wellness products in new international markets beginning Q1 2026.
• Exploring joint venture opportunities where partners will fund inventory and operational costs, reducing capital contribution requirements for Stemtech.

Negatives

• Net sales decreased significantly by 47.4% in Q2 2025 and 42.2% for the six-month period compared to the prior year, attributed to a strategic shift away from short-term volume growth and promotional pricing.
• The company has experienced recurring net losses and negative cash flows from operations since inception.
• An accumulated deficit of approximately $32.6 million and a working capital deficiency of approximately $6.4 million as of June 30, 2025, raise substantial doubt about the company's ability to continue as a going concern.
• The company is not currently profitable and cannot provide assurance of when it will be profitable.
• The company relies heavily on debt and equity financing to fund its activities.
• Outstanding principal balance of convertible promissory notes totaling $166,964 is owed to related parties (COO and Director) as of June 30, 2025.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring net losses and negative cash flows.
• The company will continue to require substantial funds to implement its new investment acquisition plans and meet operating cash flow requirements.
• Future issuances of equity or convertible debt securities will result in dilution to current shareholders.
• New securities issued in future capital transactions might have rights, preferences, or privileges senior to common stock.
• The company may incur substantial costs (investment banking, legal, accounting fees) in pursuing future capital and financing.
• Non-cash expenses may be recognized in connection with certain securities (convertible notes, warrants), adversely impacting financial condition.
• The availability or cost of future financing may be impaired by capital market conditions, particularly in the nutraceutical industry.
• If adequate funds are not available on acceptable terms, the company may not be able to take advantage of new business endeavors or opportunities, potentially restricting business operations.
• There is a risk of ceasing operations if the amount of capital raised from financing activities and operational revenue is insufficient to satisfy capital needs.
• Ongoing legal proceeding with a former CEO claiming $267,000 in unpaid salary and vacation pay, with the company having accrued this amount as a liability.

Future Outlook

The company plans to expand its presence domestically and internationally, aiming to increase its Independent Business Partner (IBP) network by 30,000 over the next 12-24 months. It is developing a Direct-to-Consumer (DTC) marketing strategy for flexible global distribution without upfront inventory. Management expects to reduce monthly cash operating expenditures by approximately $0.5 million (20%) by the end of Q3 2025 and projects a 15-20% increase in quarterly revenue compared to Q2 2025 levels by launching existing wellness products in new international markets beginning Q1 2026. The company also intends to pursue joint venture opportunities where partners will fund inventory and operational costs. Contingency plans include additional cost reductions of up to $1.0 million annually and exploring strategic partnerships if capital raising efforts are delayed or yield lower proceeds.

Management Comments

• The current quarter reflects the company's ongoing shift toward streamlining operations and focusing on long-term distributor quality and sustainability rather than short-term volume growth.
• This period of recalibration has allowed us to focus resources on core, high-performing markets and reduce dependency on lower-margin geographies and begin implementing improvements in customer engagement and retention tools, which are expected to yield benefits in upcoming quarters.
• We phased out promotional pricing structures that, while boosting top-line figures in prior periods, did not align with our margin improvement strategy.
• The improvement in cost of goods sold was driven by the company's focus on efficiency improvements and cost management strategies, despite the reduction in sales.
• The reduction in operating expenses was largely attributed to our effective cost management initiatives, which included strategic reductions in commissions and selling and marketing expenses.
• The decrease in net loss was primarily due to lower operating expenses associated with strategic investments aimed at positioning the company for future growth.
• Despite these short-term impacts on sales, we are optimistic about the long-term benefits of this recalibration, which includes strengthened customer engagement and retention programs that are expected to contribute to sustainable growth in future quarters.
• As the pioneer in stem cell nutrition, Stemtech is well positioned for growth as awareness increases.

Industry Context

Stemtech operates in the global stem cell market, which includes stem cell therapy and pharma, projected to reach $30 billion by 2030. The company positions itself as a pioneer in 'stem cell nutrition,' aiming to capitalize on increasing awareness of stem cell benefits for health. Its network marketing and direct-to-consumer models align with trends in the wellness and e-commerce sectors, particularly in a post-pandemic economy leveraging social and gig economies.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• A lawsuit filed on August 6, 2019, by a former CEO against Stemtech HealthSciences Corp. alleging unpaid salary and vacation pay totaling approximately $267,000. The company has accrued this amount and filed a counterclaim, considering the claims without merit. The litigation remains ongoing despite the court dismissing the former CEO's request for summary judgment on March 3, 2023.

Related Party Transactions

• John W. Meyer, President and COO, provided a loan of $105,000 to the company in 2024 with 18% interest.
• On February 20, 2025, John W. Meyer made another loan of $25,000 to the company with 18% interest.
• On March 19, 2024, 900,000 shares of common stock (fair value $45,000) were issued to the Chief Financial Officer as stock-based compensation.
• On March 19, 2024, an aggregate of 5,000,000 shares of common stock (fair value $150,000) were issued to five directors as stock compensation.
• On March 6, 2025, 5,000,000 shares (fair value $150,000) were issued to five directors as stock compensation.
• The company amortized $440,256 in stock compensation expense in 2024 and $217,722 in H1 2025 related to awards granted to its Chairman and CEO.
• As of June 30, 2025, the company owed outstanding principal balance of convertible promissory notes of $141,964 to Mr. John W. Meyer (COO and President) and $25,000 to Mr. Darryl V. Green (Director).

Stakeholder Impact

• Shareholders face significant dilution risk from planned future equity issuances and potential senior rights of new securities.
• Creditors (especially noteholders and factoring providers) are critical for the company's short-term liquidity, but the 'going concern' warning indicates elevated risk.
• Employees may face further headcount rationalization if capital raising efforts are delayed or insufficient.
• Independent Business Partners (IBPs) are central to the company's growth strategy, with plans to significantly increase their numbers and enhance compensation, potentially benefiting this group.
• Customers may experience improved engagement and retention tools as part of the company's recalibration strategy, but also potential shifts in product availability due to strategic market focus.

Next Steps

• Actively pursue private placement of common stock to raise approximately $57 million by Q4 2025.
• Negotiate and close a convertible debt facility of up to $3 million by Q1 2026.
• Reduce monthly cash operating expenditures by approximately $0.5 million (20%) by the end of Q3 2025.
• Launch existing wellness products in new international markets beginning Q1 2026 to increase quarterly revenue by 15-20% compared to Q2 2025 levels.
• Pursue joint venture opportunities to expand into new markets through retail and wholesale distribution models.
• Implement additional cost reductions of up to $1.0 million annually if capital raising efforts are delayed or proceeds are lower than expected.
• Explore potential strategic partnerships for supplemental liquidity.

Key Dates

Recommendation

Stemtech Corporation is in a highly distressed financial state, evidenced by a substantial accumulated deficit, a significant working capital deficiency, and an explicit 'going concern' warning. While management has made efforts to reduce net loss through aggressive cost-cutting, the drastic decline in net sales indicates fundamental business challenges. The company's survival is contingent on successful capital raises, which are inherently uncertain and will lead to significant shareholder dilution. The high level of related-party debt and ongoing litigation further compound the risks. For a seasoned investor, the risk of capital loss far outweighs any potential upside, making a 'strong sell' recommendation appropriate.

Keywords

Stem Cell Nutrition, Wellness Products, Network Marketing, Direct-to-Consumer, Nutraceuticals, SEC Filing, 10-Q, Financial Results, Liquidity, Going Concern, Capital Raise, Cost Management, Global Market, Distributor Network